Resources
7 Results (showing 1 - 7)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 3/21/2022 (updated 3/27/2024)
People who inject drugs (PWID) are likely to experience wounds and infection related to their injection drug use. Common wounds and infections experienced by PWID include blood poisoning (septicemia), infection of the heart lining (endocarditis), tetanus, hepatitis, bruising, collapsed veins, abscesses and blood clots. Preventing and caring for wounds in PWID requires special consideration of the conditions surrounding drug use.
Posted 10/25/2022 (updated 3/27/2024)
The U.S. Government Accountability Office (GAO) published a new report to Congress on access to obstetric care in rural communities. GAO found that the number of rural hospitals providing obstetric services declined from 2004 through 2018. By 2018 more than half of rural counties lacked OB services. OB closures were focused in rural counties that were sparsely populated, had a majority of Black residents, and were considered low income. GAO interviewed stakeholders to identify the most important factors affecting availability of OB care and the efforts federal agencies, states, and others could take to increase availability of services.
Posted 8/18/2020 (updated 3/28/2024)
This guide was created for harm reduction medical staff and volunteers as a resource about the types of wounds common with injection drug use and also to increase knowledge about treatment modalities for this population. Skin and soft-tissue infections are the most common cause of hospitalization among people who inject drugs.
Posted 11/27/2019 (updated 3/28/2024)
This guide is aimed at people who inject drugs to help reduce some of the problems caused by injecting.
Posted 11/10/2020 (updated 4/3/2024)
In the context of the trends in Oregon SUD metrics and the increasing infectious complications related to IDU in other jurisdictions and their implications for HIV and HCV transmission, we sought to 1) describe statewide trends in IDU-related serious bacterial infections (SBI) hospitalizations overall and by SBI type and drug use diagnosis, 2) assess IDU-related SBI diagnoses among individuals living with HIV and HCV, and 3) and determine the annual costs of IDU-related SBI overall and by SBI type.
Posted 5/26/2021 (updated 4/10/2024)
Posted 10/19/2023 (updated 4/11/2024)
Implementation IV grantees with tools and strategies